Sign in

You're signed outSign in or to get full access.

Garrett Brookman

Vice President and Equity Research Analyst at William Blair

Garrett Brookman is a Vice President and Equity Research Analyst at William Blair, specializing in coverage of the life sciences and medical technology sectors. He covers a range of companies within the diagnostics, genomics, and biotechnology industries, delivering insightful research for institutional investors but specific investment performance metrics and third-party rankings are not publicly available. Brookman began his career in financial analysis after completing his studies in biomedical engineering at Northwestern University and joined William Blair in 2021 following prior analytical roles in the health sciences industry. He holds industry certifications including FINRA Series 7 and 63 licenses, establishing his professional credentials in equity research.

Garrett Brookman's questions to QUALYS (QLYS) leadership

Question · Q3 2025

Garrett Brookman, on behalf of Jonathan Ho of William Blair, asked about the expected contribution from new product innovations (AI, new VMDR modules, ROC) versus upsell/cross-sell to the existing install base, and the traction and customer conversations around the ROC solution.

Answer

CEO Sumedh Thakar stated that Qualys doesn't break out individual modules but highlighted TotalCloud's 5% booking contribution and the focus on up-leveling VMDR customers to ETM, which includes CSAM and leads to upsells for Eliminate. He described customer conversations around ROC as 'super positive,' emphasizing its differentiation through CRQ, business focus on risk management, native rapid fixing, and AI-based intelligence, leading to a 20% increase in ROCON attendance.

Ask follow-up questions

Fintool

Fintool can predict QUALYS logo QLYS's earnings beat/miss a week before the call